Literature DB >> 35156670

The potential of probiotics in the amelioration of hyperuricemia.

Hongyuan Zhao1, Zhaoxin Lu1, Yingjian Lu2.   

Abstract

Hyperuricemia is a common disease caused by metabolic disorders or the excessive intake of high-purine foods. Persistent hyperuricemia in extreme cases induces gout, and asymptomatic hyperuricemia is probably linked to other metabolic diseases, such as hypertension. The typical damage caused by asymptomatic hyperuricemia includes inflammation, oxidative stress and gut dysbiosis. Probiotics have broad potential applications as food additives, not as drug therapies, in the amelioration of hyperuricemia. In this review, we describe novel methods for potential hyperuricemia amelioration with probiotics. The pathways through which probiotics may ameliorate hyperuricemia are discussed, including the decrease in uric acid production through purine assimilation and XOD (xanthine oxidase) inhibition as well as enhanced excretion of uric acid production by promoting ABCG2 (ATP binding cassette subfamily G member 2) activity, respectively. Three possible probiotic-related therapeutic pathways for alleviating the syndrome of hyperuricemia are also summarized. The first mechanism is to alleviate the oxidation and inflammation induced by hyperuricemia through the inhibition of NLRP3 inflammasome, the second is to restore damaged intestinal epithelium barriers and prevent gut microbiota dysbiosis, and the third is to enhance the innate immune system by increasing the secretion of immunoglobulin A (sIgA) to resist the stimulus by hyperuricemia. We propose that future research should focus on superior strain resource isolation and insight into the cause-effect mechanisms of probiotics for hyperuricemia amelioration. The safety and effects of the application of probiotics in clinical use also need verification.

Entities:  

Mesh:

Year:  2022        PMID: 35156670     DOI: 10.1039/d1fo03206b

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  4 in total

1.  The impact of short-chain fatty acid-producing bacteria of the gut microbiota in hyperuricemia and gout diagnosis.

Authors:  Gabriela A Martínez-Nava; Eder O Méndez-Salazar; Janitzia Vázquez-Mellado; Yessica Zamudio-Cuevas; Adriana Francisco-Balderas; Karina Martínez-Flores; Javier Fernández-Torres; Carlos Lozada-Pérez; Dafne L Guido-Gómora; Laura E Martínez-Gómez; Guadalupe E Jiménez-Gutiérrez; Carlos Pineda; Luis H Silveira; Laura Sánchez-Chapul; Roberto Sánchez-Sánchez; María Del Carmen Camacho-Rea; Carlos Martínez-Armenta; Ana I Burguete-García; Citlalli Orbe-Orihuela; Alfredo Lagunas-Martínez; Berenice Palacios-González; Alberto López-Reyes
Journal:  Clin Rheumatol       Date:  2022-10-06       Impact factor: 3.650

2.  Lactobacillus paracasei X11 Ameliorates Hyperuricemia and Modulates Gut Microbiota in Mice.

Authors:  Jiayuan Cao; Qiqi Liu; Haining Hao; Yushan Bu; Xiaoying Tian; Ting Wang; Huaxi Yi
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 3.  Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout.

Authors:  Zhilei Wang; Yuchen Li; Wenhao Liao; Ju Huang; Yanping Liu; Zhiyong Li; Jianyuan Tang
Journal:  Front Cell Infect Microbiol       Date:  2022-08-10       Impact factor: 6.073

4.  Probiotic Limosilactobacillus fermentum GR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid.

Authors:  Shuai Zhao; Pengya Feng; Xiaogang Hu; Wenjuan Cao; Pu Liu; Huawen Han; Weilin Jin; Xiangkai Li
Journal:  iScience       Date:  2022-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.